Publications
Selected publications
- Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping (Journal article - 2022)
- Care delivery and self-management strategies for children with epilepsy (Journal article - 2022)
- Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures (Journal article - 2021)
- Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation (Journal article - 2020)
- A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine (Journal article - 2019)
- Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. (Journal article - 2019)
- The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation (Journal article - 2016)
- Care delivery and self management strategies for adults with epilepsy (Journal article - 2016)
2024
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Fleeman, N., Houten, R., Nevitt, S., Mahon, J., Beale, S., Boland, A., . . . Waddell, T. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.. Health technology assessment (Winchester, England), 28(49), 1-190. doi:10.3310/trrm4238
Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses.
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (2024). Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses.. The Lancet. Respiratory medicine, 12(4), 281-293. doi:10.1016/s2213-2600(23)00427-7
2023
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-z
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2
Service delivery, behavioural, and self‐management interventions for adults with epilepsy
Huang, Y., Fleeman, N., Doherty, A. J., Wilson, N., Boland, P., Clegg, A., . . . Marson, A. G. (2023). Service delivery, behavioural, and self‐management interventions for adults with epilepsy. The Cochrane database of systematic reviews, 2023(3).
Service delivery, behavioural, and self‐management interventions for children with epilepsy
Fleeman, N., Panebianco, M., Hill, R. A., Doherty, A. J., Nevitt, S. J., Boland, P., . . . Marson, A. G. (2023). Service delivery, behavioural, and self‐management interventions for children with epilepsy. The Cochrane database of systematic reviews, 2023(3).
2022
Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping
Nix, E., Fleeman, N., Lorenzetti, F., Lewis, J., Shen, G., Abebe, L., . . . Puzzolo, E. (2022). Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping. ENVIRONMENTAL RESEARCH LETTERS, 17(12). doi:10.1088/1748-9326/aca1d2
Health Effects of Liquid and Gaseous Fuels for Household Energy Use: Systematic Evidence Mapping
Care delivery and self-management strategies for children with epilepsy
Fleeman, N., Bradley, P. M., Panebianco, M., & Sharma, A. (2022). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD006245.pub5
2021
Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures
Pope, D., Johnson, M., Fleeman, N., Jagoe, K., Duarte, R., Maden, M., . . . Lewis, J. (2021). Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures. ENVIRONMENTAL RESEARCH LETTERS, 16(8). doi:10.1088/1748-9326/ac13ec
A systematic review of health state utility values for thyroid cancer
Houten, R., Fleeman, N., Kotas, E., Boland, A., Lambe, T., & Duarte, R. (2021). A systematic review of health state utility values for thyroid cancer. QUALITY OF LIFE RESEARCH, 30(3), 675-702. doi:10.1007/s11136-020-02676-2
2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020
2019
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7
Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Mahon, J., Nevitt, S., Duarte, R., Boland, A., Kotas, E., . . . Ahmad, S. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(4), 453-461. doi:10.1007/s41669-019-0138-z
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-z
Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis.
Fleeman, N., Dundar, Y., Shah, P. S., & Shaw, B. N. J. (2019). Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 35(4), 298-306. doi:10.1017/S0266462319000424
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12)
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
Care delivery and self-management strategies for children with epilepsy
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.C.D006245.pub4
Care delivery and self-management strategies for children with epilepsy.
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy.. The Cochrane database of systematic reviews, 3, CD006245. doi:10.1002/14651858.cd006245.pub4
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3
2017
An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.
Martin, A., Downing, J., Maden, M., Fleeman, N., Alfirevic, A., Haycox, A., & Pirmohamed, M. (2017). An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. PHARMACOGENOMICS, 18(16), 1541-1550. doi:10.2217/pgs-2017-0076
Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman, N., Bagust, A., Boland, A., Beale, S., Richardson, M., Krishan, A., . . . Payne, M. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35(10), 1035-1046. doi:10.1007/s40273-017-0504-6
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
2016
Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Eribulin for locally advanced or metastatic breast cancer
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation
Fleeman, N., Mahon, J., Bates, V., Dickson, R., Dundar, Y., Dwan, K., . . . Shaw, B. N. J. (2016). The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 20(30), 1-67. doi:10.3310/hta20300
Care delivery and self management strategies for adults with epilepsy
Bradley, P. M., Lindsay, B., & Fleeman, N. (2016). Care delivery and self management strategies for adults with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD006244.pub3
Talimogene laherparepvec for treating metastatic melanoma
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
2015
Care delivery and self management strategies for children with epilepsy
Fleeman, N., Bradley, P. M., & Lindsay, B. (2015). Care delivery and self management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD006245.pub3
The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19(87), 1-+. doi:10.3310/hta19870
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Ciclosporin for treating dry eye disease
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dwan, K., Kotas, E., . . . Ahmad, S. (2015). Ciclosporin for treating dry eye disease: Ciclosporin for treating dry eye disease (13/166/01). NICE Website. Retrieved from https://www.nice.org.uk/
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2
Economic evaluations of personalized medicine: existing challenges and current developments
Shabaruddin, F. H., Fleeman, N. D., & Payne, K. (2015). Economic evaluations of personalized medicine: existing challenges and current developments. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 8, 115-126. doi:10.2147/PGPM.S35063
Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis
Protogerou, C., Fleernan, N., Dwan, K., Richardson, M., Dundar, Y., & Hagger, M. S. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. BEHAVIOUR RESEARCH AND THERAPY, 73, 151-164. doi:10.1016/j.brat.2015.08.004
Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
Fleeman, N., Bagust, A., Beale, S., Dwan, K., Dickson, R., Proudlove, C., & Dundar, Y. (2015). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33(1), 13-23. doi:10.1007/s40273-014-0206-2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290
2014
Deferasirox for managing iron overload in people with myelodysplastic syndrome
Meerpohl, J. J., Schell, L. K., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD007461.pub3
Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer
Fleeman, N., Bagust, A., Boland, A., Dwan, K., Chaplin, M., Beale, S., . . . Greystoke, A. (2014). Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer: Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer (13/106/01). NICE Website. Retrieved from https://www.nice.org.uk/
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Deferasirox for managing transfusional iron overload in people with sickle cell disease
Meerpohl, J. J., Schell, L. K., Ruecker, G., Motschall, E., Fleeman, N., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5), 1-77. doi:10.1002/14651858.CD007477.pub3
Allopurinol for the treatment of chronic kidney disease: a systematic review
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K., Boland, A., Dickson, R., . . . Pyatt, J. (2014). Allopurinol for the treatment of chronic kidney disease: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 18(40), 1-+. doi:10.3310/hta18400
EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS
Protogerou, C., Fleeman, N. F., Dwain, K. D., Richardson, M. R., Dundar, Y. D., & Dickson, R. D. (2014). EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS. In INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE Vol. 21 (pp. S63). Retrieved from https://www.webofscience.com/
2013
Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen
Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., . . . Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen. PERSONALIZED MEDICINE, 10(6), 601-611. doi:10.2217/pme.13.60
2012
Deferasirox for managing iron overload in people with thalassaemia
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2012). Deferasirox for managing iron overload in people with thalassaemia. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD007476.pub2
2011
The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., . . . Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 15(33), XIII-+. doi:10.3310/hta15330
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., . . . Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. PHARMACOGENOMICS JOURNAL, 11(1), 1-14. doi:10.1038/tpj.2010.73
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420
2010
Deferasirox for managing iron overload in people with myelodysplastic syndrome
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2010). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (11). doi:10.1002/14651858.CD007461.pub2
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05
Deferasirox for managing transfusional iron overload in people with sickle cell disease
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Niemeyer, C., & Bassler, D. (2010). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD007477.pub2
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05
Abatacept for the treatment of rheumatoid arthritis
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1). doi:10.3310/hta14suppl1/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030
2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (n.d.). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (n.d.). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04
Providing patients with information on pharmacogenetic testing
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing. Nursing Standard, 23(21), 46-51. doi:10.7748/ns.23.21.46.s51
Providing patients with information on pharmacogenetic testing.
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing.. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 23(21), 46-48. doi:10.7748/ns2009.01.23.21.46.c6768
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010
Rituximab for the treatment of rheumatoid arthritis
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04
2008
Deferasirox for managing iron overload in patients with myelodysplastic syndrome
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing iron overload in patients with myelodysplastic syndrome. doi:10.1002/14651858.cd007461
Deferasirox for managing iron overload in people with thalassaemia
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C. M., & Bassler, D. (n.d.). Deferasirox for managing iron overload in people with thalassaemia. doi:10.1002/14651858.cd007476
Deferasirox for managing transfusional iron overload in people with sickle cell disease
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing transfusional iron overload in people with sickle cell disease. doi:10.1002/14651858.cd007477
So many filters, so little time: the development of a search filter appraisal checklist
Glanville, J., Bayliss, S., Booth, A., Dundar, Y., Fernandes, H., Fleeman, N. D., . . . Welch, K. (2008). So many filters, so little time: the development of a search filter appraisal checklist. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 96(4), 356-361. doi:10.3163/1536-5050.96.4.011
2000
A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS)
Fleeman, N., & Scott-Samuel, A. (2000). A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS). JOURNAL OF PUBLIC HEALTH MEDICINE, 22(3), 268-274. Retrieved from https://www.webofscience.com/
1997
Alcohol home detoxification: a literature review.
Fleeman, N. D. (1997). Alcohol home detoxification: a literature review.. Alcohol and alcoholism (Oxford, Oxfordshire), 32(6), 649-656. doi:10.1093/oxfordjournals.alcalc.a008315
Undated
Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (n.d.). Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis.